- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Laryngeal involvement in mucous membrane pemphigoid predicts poor response to rituximab: IJDVL
Laryngeal mucous membrane pemphigoid a poor prognostic factor for rituximab treatment: IJDVL
Mucous membrane pemphigoid (MMP) is an autoimmune subepidermal bullous disease with a tendency to scar and may progress to blindness or airway obstruction. When it involves the eyes or larynx, Mucous membrane pemphigoid (MMP) tends to be refractory to conventional treatments and rituximab (RTX) has emerged as a potential therapeutic solution for MMP in the past few years. Recently a case series with a review describing the use of rituximab in MMP was described in the Clinical and Experimental Dermatology journal.
It was a case series of 4 patients of MMP who were diagnosed on the basis of typical clinical features, histology and direct immunofluorescence study.
All patients were women (mean age 72 years at the initiation of RTX treatment). Three patients had oral and laryngeal disease. Ocular and oesophageal disease were seen in one patient each. The mean duration of disease before RTX therapy was 40.75 months (range 7– 84 months). All patients had failure with at least one systemic treatment. All the patients were treated with two infusions of RTX (1 g each, given on Days 1 and 15).
In the series all 3 patients had commenced treatment with inflammatory erosive laryngeal lesions without evidence of significant scarring. 2/3 patients with laryngeal involvement had no response to RTX treatment. The third patient achieved complete remission (CR) for 2 years with subsequent relapses every 2 years which responded well to an additional RTX cycle each time.. Patient 4, who did not have laryngeal involvement achieved CR and was lost to follow-up.
A literature search was done which revealed 30 articles including 167 patients of MMP treated with RTX. Late observation endpoints (defined as outcome after at least 2 months of therapy) were noted for 144 patients, of whom 100 (69.4%) achieved CR, 26 (18%) achieved partial remission (PR) and 18 (12.5%) had no remission (NR). In total CR or PR were achieved with RTX treatment in 87.5% of patients with MMP.
Different outcomes were noted in the same patient, as certain anatomical sites responded differently to RTX treatment. Of all sites, the larynx seemed to be the most refractory to RTX treatment. In total only 40% of patients with laryngeal involvement achieved CR, whereas other sites achieved CR rates of 67%–80% (P = 0.014).
Of the 7 laryngeal MMP cases recalcitrant to RTX, 2 did not respond to additional cycles of RTX, and one remained unresponsive despite therapy with intravenous immunoglobulins (IVIG). Of the six patients with laryngeal disease who achieved CR, four were taking concomitant immunosuppressive therapy making it difficult to draw conclusions about RTX efficiency.
In conclusion rituximab is a potent therapy for MMP and relapses after RTX are frequent so maintenance therapy should be considered. Laryngeal involvement in patients with MMP may predict poor response to rituximab and in view of its serious consequences of local scarring, prompt combination therapy should be considered for these MMP cases.
Source- Baniel A, Oestreicher-Kedem Y, Peled A, Bar-Ilan E, Geller S, Sprecher E, Baum S. Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab. Clin Exp Dermatol. 2021 Jul;46(5):915-919. doi: 10.1111/ced.14662. Epub 2021 May 27. PMID: 33811681
MBBS
Dr Manoj Kumar Nayak has completed his M.B.B.S. from the prestigious institute Bangalore medical college and research institute, Bengaluru. He completed his M.D. Dermatology from AIIMS Rishikesh. He is actively involved in the field of dermatology with special interests in vitiligo, immunobullous disorders, psoriasis and procedural dermatology. His continued interest in academics and recent developments serves as an inspiration to work with medical dialogues.He can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751